NCT07141407

Brief Summary

This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and their support person. Participation in ACP, which includes having end of life (EOL) care conversations and completing advance directives (e.g., living will, health care proxy, do not resuscitate order), improves quality EOL care. Despite this, less than half of patients with advanced cancer have EOL care conversations or complete advance directives. TAC coaching sessions are delivered by a social worker over the phone. They are designed to help patients and their support person communicate about ACP, manage the distress these conversations can cause, and participate in the process of ACP with a clear action plan of having goals-of-care conversations and completing advance directives. This may be an effective way to improve ACP participation in advanced cancer patients and their support person.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
6mo left

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress27%
Apr 2026Dec 2026

First Submitted

Initial submission to the registry

August 19, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 26, 2025

Completed
8 months until next milestone

Study Start

First participant enrolled

April 8, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 12, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 14, 2026

Last Updated

May 29, 2026

Status Verified

February 1, 2026

Enrollment Period

6 months

First QC Date

August 19, 2025

Last Update Submit

May 27, 2026

Conditions

Outcome Measures

Primary Outcomes (4)

  • Enrollment rate (Feasibility)

    Feasibility will be examined using enrollment rates. Feasibility cutoffs will be based on prior research and include the following: ≥ 50% of eligible participants will enroll in the study. Low rates of enrollment, including missing data, will indicate low feasibility.

    At 6-weeks post-randomization

  • Intervention session completion rate (Feasibility)

    Feasibility will be examined using enrollment and intervention completion rates as outcomes. Feasibility cutoffs will be based on prior research and include the following: ≥ 75% of Talking About Cancer sessions will be delivered with fidelity.

    At 6-weeks post-randomization

  • Acceptability of Intervention Measure (AIM) score (Acceptability)

    To analyze intervention acceptability, will examine the median score for the AIM measure, with a median of \>= 4 indicating acceptability (on a 5-point Likert scale where 4=Agree and 5=Completely agree and higher scores indicate higher levels of acceptability).

    At 6-weeks post-randomization

  • Completion rate of study assessments (Feasibility of collecting primary and secondary outcomes)

    Feasibility of the study collection procedures will be examined using study-related assessment completion rates and includes the following: ≥ 50% of enrolled patients will adhere to and complete assigned intervention components and study-related assessments.

    At baseline, 6-weeks post- randomization, and 12-weeks post-randomization

Secondary Outcomes (11)

  • Completion of advance directives

    At baseline, 6-weeks post-randomization, and 12-weeks post-randomization

  • Completion of do not resuscitate (DNR) order

    At baseline, 6-weeks post-randomization, 12-weeks post-randomization

  • Completion of living will

    At baseline, 6-weeks post-randomization, and 12-weeks randomization

  • Identification of a health care proxy

    At baseline, 6-weeks post-randomization, and 12-weeks post-randomization

  • Advance care planning (ACP) conversations

    At baseline, 6-weeks post-randomization, and 12-weeks post-randomization

  • +6 more secondary outcomes

Study Arms (2)

Arm I (TAC sessions)

EXPERIMENTAL

Participants attend Talking About Cancer (TAC) telephone-based coaching sessions (2 sessions) designed to support participants in communicating about advance care planning (ACP), managing distress around ACP conversations, engaging in the process of ACP, and completing advance directives over 45-60 minutes each once a week (QW) for 2 weeks.

Other: Supportive CareBehavioral: Telephone-Based InterventionOther: Survey Administration

Arm II (enhanced usual care)

ACTIVE COMPARATOR

Participants receive an ACP brochure/handout on study.

Other: Survey AdministrationOther: Educational Intervention

Interventions

Attend TAC telephone-based coaching sessions

Arm I (TAC sessions)

Ancillary studies

Arm I (TAC sessions)Arm II (enhanced usual care)

Receive an ACP brochure/handout

Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Arm II (enhanced usual care)

Attend TAC telephone-based coaching sessions

Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive
Arm I (TAC sessions)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • PATIENT: Current diagnosis of stage III or IV cancer
  • PATIENT: Able to provide informed consent
  • PATIENT: Fluent in English or Spanish
  • PATIENT: Have access to a telephone, computer, or mobile device
  • CAREGIVER (SUPPORT PERSON): Person patient indicates provides support
  • CAREGIVER (SUPPORT PERSON): English or Spanish speaking
  • CAREGIVER (SUPPORT PERSON): 18 years of age or older
  • CAREGIVER (SUPPORT PERSON): Able to provide informed consent

You may not qualify if:

  • PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer)
  • PATIENT: Receiving hospice at the time of enrollment
  • PATIENT: Younger than age 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Providence Regional Cancer Partnership

Everett, Washington, 98201, United States

RECRUITING

Skagit Regional Health Cancer Care Center

Mount Vernon, Washington, 98274, United States

RECRUITING

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

RECRUITING

MeSH Terms

Interventions

Palliative CareEarly Intervention, EducationalEducational StatusMethods

Intervention Hierarchy (Ancestors)

Patient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and ServicesChild Health ServicesCommunity Health ServicesPreventive Health ServicesSocioeconomic FactorsPopulation CharacteristicsInvestigative Techniques

Study Officials

  • Megan Shen, PhD

    Fred Hutch/University of Washington Cancer Consortium

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Megan Shen, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Masking Details
The study project coordinator will oversee randomization and the research coordinator conducting assessments will remain blind to the condition to which the participant is assigned.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2025

First Posted

August 26, 2025

Study Start

April 8, 2026

Primary Completion (Estimated)

October 12, 2026

Study Completion (Estimated)

December 14, 2026

Last Updated

May 29, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations